Answers are grounded in this paper and cite their sources.
Case report shows sustained efficacy and low thrombosis rates in bioresorbable scaffolds, suggesting careful imaging post-resorption.
Bioresorbable vascular scaffolds offer temporary mechanical support and local drug delivery to coronary arteries, ultimately restoring native vessel physiology after resorption. This case describes a 62-year-old man who underwent percutaneous coronary intervention with a second-generation sirolimus-eluting MeRes100 scaffold for significant proximal left anterior descending artery stenosis. Four years post-implantation, the patient remained asymptomatic but presented with intermittent, atypical chest pain. Coronary computed tomography angiography revealed complete scaffold resorption and preserved vessel patency, though interpretation was complicated by blooming artefacts from residual metallic markers. Second-generation scaffolds like MeRes100 show improved mechanical properties, predictable bioresorption profiles, and excellent clinical outcomes, including low rates of thrombosis and restoration of vasomotion. This case highlights both the long-term safety and efficacy of MeRes100 and the limitations posed by imaging artefacts, emphasizing the need for cautious computed tomography interpretation after scaffold resorption.
No takes yet. Share an insight, caveat, or question.
Polamuri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: